Find, compare & contact
Nivocasan
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Nivocasan API 908253-63-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Nivocasan. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Nivocasan
- Synonyms:
- Cas Number:
- 908253-63-4
- DrugBank number:
- DB12720
- Unique Ingredient Identifier:
- 9554OW6MVU
General Description:
Nivocasan, identified by CAS number 908253-63-4, is a notable compound with significant therapeutic applications. Nivocasan has been used in trials studying the treatment of HCV Infection and Nonalcoholic Steatohepatitis.
Classification:
Nivocasan belongs to the class of organic compounds known as isoquinolines and derivatives. These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine, classified under the direct parent group Isoquinolines and derivatives. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Isoquinolines and derivatives class, specifically within the None subclass.
Nivocasan is a type of Anti-HCV agents
Anti-HCV agents, belonging to the pharmaceutical API category, are potent medications used in the treatment of Hepatitis C Virus (HCV) infection. Hepatitis C is a viral disease that affects the liver and can lead to severe health complications if left untreated. Anti-HCV agents work by targeting specific mechanisms involved in the replication and spread of the HCV virus within the body.
These pharmaceutical APIs are designed to inhibit various steps of the viral lifecycle, including viral entry into liver cells, viral RNA replication, and assembly of new viral particles. By disrupting these critical processes, anti-HCV agents effectively reduce the viral load in the body, slow down disease progression, and ultimately improve patient outcomes.
The development of anti-HCV agents has revolutionized the management of HCV infection, offering new hope for patients. These APIs are often used in combination with other antiviral drugs to form highly effective treatment regimens known as direct-acting antiviral (DAA) therapies. DAAs have significantly higher cure rates compared to older treatment options, such as interferon-based therapies, and are associated with fewer side effects.
The pharmaceutical industry has made significant advancements in the development of anti-HCV agents, resulting in a diverse range of APIs with varying mechanisms of action. This diversity allows healthcare professionals to tailor treatment plans based on the specific characteristics of each patient's HCV infection, maximizing the chances of successful viral eradication.
In summary, anti-HCV agents are a crucial category of pharmaceutical APIs used in the treatment of Hepatitis C. Their targeted action against the HCV virus has revolutionized the management of this chronic infection, providing more effective and better-tolerated treatment options for patients.
